TR201809128T4 - Gram-pozitif bakterilere spesifik bağlanan bileşikler. - Google Patents

Gram-pozitif bakterilere spesifik bağlanan bileşikler. Download PDF

Info

Publication number
TR201809128T4
TR201809128T4 TR2018/09128T TR201809128T TR201809128T4 TR 201809128 T4 TR201809128 T4 TR 201809128T4 TR 2018/09128 T TR2018/09128 T TR 2018/09128T TR 201809128 T TR201809128 T TR 201809128T TR 201809128 T4 TR201809128 T4 TR 201809128T4
Authority
TR
Turkey
Prior art keywords
sequence
seq
antibody
light chain
heavy chain
Prior art date
Application number
TR2018/09128T
Other languages
English (en)
Inventor
Beaumont Tim
Jeroen Kwakkenbos Mark
Eric Brown J
Hiroshi Morisaki John
W Wouter Hazenbos L
Mariathasan Sanjeev
Kajihara Kimberly
Xia Yi
Original Assignee
Aimm Therapeutics Bv
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aimm Therapeutics Bv, Genentech Inc filed Critical Aimm Therapeutics Bv
Publication of TR201809128T4 publication Critical patent/TR201809128T4/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1271—Micrococcaceae (F); Staphylococcaceae (F), e.g. Staphylococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1278—Bacillus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/10—Detection of antigens from microorganism in sample from host
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/26—Infectious diseases, e.g. generalised sepsis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physiology (AREA)
  • Tropical Medicine & Parasitology (AREA)

Abstract

Bu buluş, Gram-pozitif bakterilere spesifik olarak bağlanabilen gelişmiş bağlanma bileşikleri ortaya koymaktadır. Tamamen insan menşeli olup bu sayede insanlara yönelik terapötik uygulamalarda kullanılabilecek olan bağlanma bileşikleri sunulmaktadır.

Claims (2)

ISTEMLER
1. Bir Staphylococcus türüne baglanma kabiliyetine sahip olan ve asagida belirtilenleri içeren bir izole antikor veya onun bir 5 fonksiyonel parçasi: (a) bir agir zincir CDRl sekansi olan RFAMS (SEKANS KOD NO.: 1), ve (b) bir agir zincir CDR2 sekansi olan 10 SINNGNNPYYARSVQY (SEKANS KOD NO.: 2), ve (c) bir agir zincir CDR3 sekansi olan DHPSSGWPTFDS (SEKANS KOD NO.: 3), ve ((1) bir hafif zincir CDRl sekansi olan RASENVGDWLA (SEKANS KOD NO.: 4), ve 15 (e) bir hafif zincir CDR2 sekansi olan KTSILES (SEKANS KOD NO.: 5), ve (I) bir hafif zincir CDR3 sekansi olan X'in I veya M oldugu QHYXRFPYT (SEKANS KOD NO.: 6). 20
2. Istem l'e uygun antikor veya onun fonksiyonel parçasi olup, burada antikor veya onun fonksiyonel parçasi asagida belirtilenleri (i) asagida belirtilenleri içeren bir agir zincir degisken 25 domain sekansi: (a) EVQLLESGGGLVQPGGSLRLSCAASGFTL S (SEKANS KOD NO.: 38) sekansina sahip olan çerçeve l (FW1); (b) WVRQAPGRGLEWVA (SEKANS KOD NO.: 40) sekansina sahip olan çerçeve 2 (FW2); (c) RFTVSRDVSQNTVSLQMNNLRAEDSATYF CAK (SEKANS KOD NO.: 42) sekansina sahip olan çerçeve 3 (FW3); ve (d) WGPGTLVTVSS (SEKANS KOD NO.: 44) sekansina sahip olan çerçeve 4 (FW4); (ii) asagida belirtilenleri içeren bir hafif zincir degisken domain sekansi: (a) DIQLTQSPSALPASVGDRVSITC (SEKANS KOD NO.: 48) sekansina sahip olan çerçeve 1 (b) WYRQKPGKAPNLLIY (SEKANS KOD NO.: 50) sekansina sahip olan çerçeve 2 (FW2); (C) GVPSRFSGSGSGTEFTLTISSLQPDDFATYY C (SEKANS KOD NO.: 52) sekansina sahip olan çerçeve 3 (FW3); ve (d) FGQGTKLEIKRTV (SEKANS KOD NO.: 54) sekansina sahip olan çerçeve 4 (FW4); veya (a) DIQLTQSPSALPASVGDRVSITC (SEKANS KOD NO.: 48) sekansina sahip olan çerçeve l (b) WYRQKPGKAPNLLIY (SEKANS KOD NO.: 50) sekansina sahip olan çerçeve 2 (FW2); (c) GVPSRFSGSGSGTEFTLTISSLQPDDFATYY C (SEKANS KOD NO.: 52) sekansina sahip olan çerçeve 3 (FW3); ve (d) FGQGTKVEIKRTV (SEKANS KOD NO.: 59) sekansina sahip olan çerçeve 4 (FW4). Istem l'e uygun antikor veya oiiun fonksiyonel parçasi olup, burada antikor veya onun fonksiyonel parçasi asagida belirtilenleri içerir: (i) EVQLLESGGGLVQPGGSLRLSCAASGFTLSRFA MSWVRQAPGRGLEWVASINNGNNPYYARSVQYR FTVSRDVSQNTVSLQMNNLRAEDSATYFCAKDHPS SGWPTFDSWGP GTLVTVSS (SEKANS KOD NO.: 7) sekansi ile en az %70 oraninda sekans özdesligine sahip olan bir sekans içeren bir agir zincir degisken domain sekansi; (ii) burada X'in 1 veya M oldugu DIQLTQSPSALPASVGDRVSITCRASENVGDWLAW YRQKPGKAPNLLIYKTSILESGVPSRFSGSGSGTEFT LTISSLQPDDFATYYCQHYXRFPYTFGQGTKLEIKR TV (SEKANS KOD NO.: 8) sekansi ile en az %70 oraninda sekans özdesligine sahip olan bir sekans içeren bir hafif zincir degisken domain sekansi. Istem 3 ”e uygun antikor veya onun fonksiyonel parçasi olup, burada antikor veya onun fonksiyonel parçasi EVQLLESGGGLVQPGGSLRLSCAASGFTLSRFAMSWVR QAPGRGLEWVASINNGNNPYYARSVQYRFTVSRDVSQN TVSLQMNNLRAEDSATYFCAKDHPSSGWPTFDSWGP GTLVTVSS (SEKANS KOD NO.: 7) sekansina sahip olan bir agir zincir degisken domaini içerir burada antikor vay onun fonksiyonel parçasi X'in 1 veya M DIQLTQSPSALPASVGDRVSITCRASENVGDWLAWYRQK PGKAPNLLIYKTSILESGVPSRFSGSGSGTEFTLTISSLQPD DFATYYCQHYXRFPYTFGQGTKVEIKRTV (SEKANS KOD NO.: 1 l) sekansina sahip olan bir hafif zincir degisken domaini içerir. Istem l'e uygun bir izole antikor veya onun fonksiyonel parçasi burada söz konusu antikor veya onun fonksiyonel parçasi istege bagli olarak insan kaynaklidir, ve burada Staphylococcus türü istege bagli olarak bir metisiline dirençli S. aureus (MRSA) veya bir inetisiline duyarli S. aureus (MSSA) veya bir vankomisine orta düzeyde duyarli S. aureus (VISA)°dir ve burada antikor veya bunun fonksiyonel parçasi asagida belirtilenlerden birini içerir: (a) EVQLLESGGGLVQPGGSLRLSCAASGFTL SRFAMSWVRQAPGRGLEWVASINNGNN PYYARSVQYRFTVSRDVSQNTVSLQMNN LRAEDSATYFCAKDHPSSGWPTFDSWGP GTLVTVSS (SEKANS KOD NO.: 7) sekansini içeren bir agir zincir degisken domaini; (b) burada X'in 1 veya M oldugu DIQLTQSPSALPASVGDRVSITCRASENVGDW LAWYRQKPGKAPNLLIYKTSILESGVPSRFSG SGSGTEFTLTISSLQPDDFATYYCQHYXRFPY TFGQGTKVEIKRTV (SEKANS KOD NO.: 1 1) sekansini içeren bir hafif zincir degisken domaini; (a) EVQLVESGGGLVQPGGSLRLSCAASGFTL SRFAMSWVRQAPGRGLEWVASINNGNNP YYARSVQYRFTVSRDVSQNTVSLQMNNL RAEDSATYFCAKDHPSSGWPTFDSWGPGT LVTVSS (SEKANS KOD NO.: 9) sekansini içeren bir agir zincir degisken domaini; (b) burada X'in 1 veya M oldugu DIQLTQSPSALPASVGDRVSITCRASENVGDW LAWYRQKPGKAPNLLIYKTSILESGV PSRFSGSGSGTEFTLTISSLQPDDFATYYCQHY XRFPYTFGQGTKLEIKRTV (SEKANS KOD NO 8) sekansini içeren bir hafif zincir degisken domaini; veya (a) EVQLVESGGGLVQPGGSLRLSCAASGFTL SRFAMSWVRQAPGRGLEWVASINNGNNP YYARSVQYRFTVSRDVSQNTVSLQMNNL RAEDSATYFCAKDHPSSGWPTFDSWGPGT LVTVSS (SEKANS KOD NO.: 9) sekansini içeren bir agir Zincir degisken domaini; (b) burada X'in 1 veya M oldugu DIQLTQSPSALPASVGDRVSITCRASENVGDW LAWYRQKPGKAPNLLIYKTSILESGV PSRFSGSGSGTEFTLTISSLQPDDFATYYCQHY XRFPYTFGQGTKLEIKRA (SEKANS KOD NO.: 10) sekansini içeren bir hafif zincir degisken domaini; veya (21) EVQLVESGGGLVQPGGSLRLSCAASGFTL SRFAMSWVRQAPGRGLEWVASINNGNNP YYARSVQYRFTVSRDVSQNTVSLQMNNL RAEDSATYFCAKDHPSSGWPTFDSWGPGT LVTVSS (SEKANS KOD NO.: 9) sekansini içeren bir agir zincir degisken domaini; (b) burada X'in 1 veya M oldugu DIQLTQSPSALPASVGDRVSITCRASENVGDW LAWYRQKPGKAPNLLIYKTSILESGV PSRFSGSGSGTEFTLTISSLQPDDFATYYCQHY XRFPYTFGQGTKVEIKRTV (SEKANS KOD NO.: 11) sekansini içeren bir hafif zincir degisken domaini; veya (21) EVQLLESGGGLVQPGGSLRLSCAASGFTL SRFAMSWVRQAPGRGLEWVASINNGNNP YYARSVQYRFTVSRDVSQNTVSLQMNNL RAEDSATYFCAKDHPSSGWPTFDSWGPGT LVTVSS (SEKANS KOD NO.: 7) sekansini içeren bir agir zincir degisken domaini; (b) burada X'in 1 veya M oldugu DIQLTQSPSALPASVGDRVSITCRASENVGDW LAWYRQKPGKAPNLLIYKTSILESGV PSRFSGSGSGTEFTLTISSLQPDDFATYYCQHY XRFPYTFGQGTKLEIKRTV (SEKANS KOD NO 8) sekansini içeren bir hafif zincir degisken domaini; veya (a) EVQLLESGGGLVQPGGSLRLSCAASGF TL SRFAMSWVRQAPGRGLEWVASINNGNNP YYARSVQYRFTVSRDVSQNTVSLQMNNL RAEDSATYFCAKDHPSSGWPTFDSWGPGT LVTVSS (SEKANS KOD NO.: 7) sekansini içeren bir agir zincir degisken domaini; (b) burada X'in 1 veya M oldugu DIQLTQSPSALPASVGDRVSITCRASENVGDW LAWYRQKPGKAPNLLIYKTSILESGV PSRFSGSGSGTEFTLTISSLQPDDFATYYCQHY XRFPYTFGQGTKLEIKRA (SEKANS KOD NO.: 10) sekansiiii içeren bir hafif zincir degisken domaini.
6. Asagida belirtilenleri içeren, istem l'e uygun bir izole antikor veya onun bir fonksiyonel parçasi: (a) SEKANS KOD NO.: 55 sekansini içeren bir agir zincir (Sekil 9A, rFl agir zinciri); ve (b) SEKANS KOD NO.: 57 sekansini içeren bir hafif zincir (Sekil 9B, rFl hafif zinciri).
7. Bir Staphylococcus türüne baglanma kabiliyetine sahip olan ve asagida belirtilenleri içeren ve asagidaki (i), (ii) ve (iii) sayili maddelerden herhangi birinde belirtilen ainino asit ikame(1er)ini bünyesinde barindiran bir izole antikor veya onun bir fonksiyonel parçasi: (a) bir agir zincir CDRl sekansi olan RFAMS (SEKANS KOD NO.: 1), ve (b) bir agir zincir CDR2 sekansi olan SINNGNNPYYARSVQY (SEKANS KOD NO.: 2), ve (0) bir agir zincir CDR3 sekansi olan DHPSSGWPTFDS (SEKANS KOD NO.: 3), ve (d) bir hafif zincir CDR] sekansi olan RASENVGDWLA (SEKANS KOD NO.: 4), ve (e) bir hafif zincir CDR2 sekansi olan KTSILES (SEKANS KOD NO.: 5), ve (f) bir hafif zincir CDR3 sekansi olan X'in 1 veya M oldugu QHYXRFPYT (SEKANS KOD NO.: 6); (i) "Kabat (1991)" eserinde gösterilen amino asit nuinaralandirma sistemine göre agir zincir degisken domaininde 53 numarali pozisyonda yer alan asparajinin baska bir amino asit ile ikamesi, amino asidin serin ile ikamesi; veya (ii) "Kabat (1991)" eserinde gösterilen amino asit nuinaralandirma sistemine göre agir zincir degisken domaininde 53 numarali pozisyonda yer alan asparajinin serin ile ikamesi, 114 numarali pozisyonda yer alan alaninin sistein ile ikamesi ve 222 numarali pozisyonda yer alan ar jininin lizin ile ikamesi; veya (iii) "Kabat (1991)" eserinde gösterilen amino asit numaralandirma sistemine göre hafif zincir degisken domaininde 205 numarali pozisyonda yer alan valinin sistein ile ikamesi, hafif zincir degisken domaininde 110 numarali pozisyonda yer alan alaniniii valin ile ikamesi ve hafif zincir degisken domaininde 104 numarali pozisyonda yer alan lösinin valin ile ikamesi. Asagida belirtileiileri içeren, istem 7'ye uygun bir izole antikor veya onun bir fonksiyonel parçasi: (a) SEKANS KOD NO.: 56 sekansini içeren bir agir zincir (Sekil 9A, rFl A1 14C); ve (b) SEKANS KOD NO.: 58 sekansini içeren bir hafif zincir (Sekil 9B, rFl V205G). Istem 1'e uygun antikorun bir fonksiyonel parçasini içeren bir bilesim olup, burada antikorun fonksiyonel parçasi bir tek domainli antikor, bir tek zincirli antikor, bir nanobody, bir unibody, bir tek zincirli degisken bölge fragmani (scFV), bir Fab fragmani ve bir F(ab')2 fragmani arasindan seçilir. Asagida belirtilenlerden birini kodlayaii bir izole, sentetik veya rekombinan iiükleik asit sekansi: (i) istem 1 ilâ 8'e uygun antikorlar veya bunun fonksiyonel parçalarindan herhangi biri; veya (ii) agir zincir CDRl, CDR2 veya CDR3 ya da hafif zincir CDRl, CDR2 veya CDR3 burada sekans asagida olusan grup arasindan seçilir: agir zincir CDRl sekansi cgctttgccatgagc (SEKANS KOD NO.: 12), agir zincir CDR2 sekansi (SEKANS KOD NO.: 13), agir zincir CDR3 sekansi gatcaccctagtagtggctggcccacctttgactcc (SEKANS KOD NO.: 14), hafif zincir CDRl sekansi cgggccagtgaaaacgttggtgactggttgg cc (SEKANS KOD NO.: 15), hafif zincir CDR2 sekansi aagacatctattctagaaagt (SEKANS KOD NO.: 16) ve hafif zincir CDR3 sekansi Caacactatatacgtttcccgtacact (SEKANS KOD NO.: 17). Istem lO'a uygun nükleik asidi içeren bir izole hücre. Bir ilaç ve/Veya profilaktik ajan olarak kullanim için, istemler 1 ilâ 8'den herhangi birine uygun bir antikor veya onun fonksiyonel parçasi ya da istem lO'a uygun bir nükleik asit sekansi. Asagida belirtilen kullanim alanlarindan birinde kullanim için, isteniler l ilâ 8'den herhangi birine uygun bir antikor veya onun fonksiyonel parçasi ya da istem lO'a uygun bir nükleik asit sekansi: (i) bir Gram-pozitif bakteri ile iliskili rahatsizligi tedavi etmeye ve/veya Önlemeye yönelik bir ilaç ve/veya profilaktik ajan olarak; veya (ii) bir Staphylococcus enfeksiyonunun in vivo ortamda teshisinde. Istemler 1 ilâ 8'de11 herhangi birine uygun bir antikor veya onun fonksiyonel parçasi ya da istein lO'a uygun bir nükleik asit sekansinin bir Gram-pozitif bakteri ile iliskili hastaligi tedavi etmeye ve/veya önlemeye yönelik bir ilaç ve/veya profilaktik a janin hazirlanma asamasinda kullanimi. Istemler l ilâ 8'den herhangi birine uygun bir antikor veya onun fonksiyonel parçasinin ya da istem 10'a uygun bir nükleik asit sekansinin bulundugu ve ayrica bir faimasötik açidan kabul edilebilir tasiyici, seyreltici veya yardimci madde ihtiva eden bir farmasötik bilesim. Isteinler 1 ilâ 8'den herhangi birine uygun bir antikor veya bir fonksiyonel antikor parçasi üretme kabiliyetine sahip olan bir izole veya rekombinan antikor üreten hücre. Istemler 1 ilâ 8'den herhangi birine uygun bir antikor veya bir fonksiyonel antikor parçasi üretmek için olan ve istem 10'a uygun bir nükleik asit sekansi bulunan bir hücrenin temin edilmesi ve o hücrenin söz konusu nükleik asit sekansini translate etmesine izin vermek suretiyle bahsi geçen antikor veya fonksiyonel antikor parçasini üretmeye dayanan ve istege bagli olarak ayrica söz konusu antikor veya fonksiyonel antikor parçasinin hasat edildigi, saflastirildigi ve/Veya izole edildigi bir yöntem. Isteniler l ilâ 8'den herhangi birine uygun bir antikor veya onun fonksiyonel parçasi ya da istem 10'a uygun bir nükleik asit sekansinin asagida belirtilen kullanim alanlarindan birinde in vitro ortamda kullanimi: (a) bir Staphylococcus enfeksiyonunun teshisi; veya (b) S. aureus ve/veya S. epiderinidis'in tespiti. Bir çözeltide bulunan S. aureus ve/Veya S. epiderinidis bakterilerini o çözeltiden isteinler l ilâ 8'den herhangi birine uygun bir antikor veya bir fonksiyonel antikor parçasi kullanarak izole etmek için olan bir yöntem.
TR2018/09128T 2009-07-15 2010-07-15 Gram-pozitif bakterilere spesifik bağlanan bileşikler. TR201809128T4 (tr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22587809P 2009-07-15 2009-07-15
EP09165558 2009-07-15

Publications (1)

Publication Number Publication Date
TR201809128T4 true TR201809128T4 (tr) 2018-07-23

Family

ID=41467048

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2018/09128T TR201809128T4 (tr) 2009-07-15 2010-07-15 Gram-pozitif bakterilere spesifik bağlanan bileşikler.

Country Status (24)

Country Link
US (9) US20110020323A1 (tr)
EP (1) EP2454284B1 (tr)
JP (3) JP6192294B2 (tr)
KR (1) KR101832201B1 (tr)
CN (2) CN102666583B (tr)
AR (1) AR077756A1 (tr)
AU (2) AU2010271582B2 (tr)
BR (1) BR112012000953A8 (tr)
CA (1) CA2768204A1 (tr)
DK (1) DK2454284T3 (tr)
EA (1) EA031447B1 (tr)
ES (1) ES2673323T3 (tr)
HK (1) HK1222418A1 (tr)
HU (1) HUE038277T2 (tr)
IL (3) IL217497A (tr)
MX (1) MX350234B (tr)
NZ (2) NZ598063A (tr)
PL (1) PL2454284T3 (tr)
SG (2) SG177653A1 (tr)
SI (1) SI2454284T1 (tr)
TR (1) TR201809128T4 (tr)
TW (2) TW201610153A (tr)
WO (1) WO2011008092A2 (tr)
ZA (2) ZA201200363B (tr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007067032A1 (en) 2005-12-09 2007-06-14 Academisch Medisch Cemtrum Bij De Universiteit Van Amsterdam Means and methods for influencing the stability of cells
DK1974017T4 (da) 2005-12-09 2023-09-25 Academisch Medisch Centrum Bij De Univ Van Amsterdam Midler og fremgangsmåder til at påvirke stabiliteten af antistof producerende celler
EP3683317A3 (en) 2009-05-13 2020-09-30 Genzyme Corporation Anti-human cd52 immunoglobulins
DK2454283T3 (en) 2009-07-15 2018-05-07 Aimm Therapeutics Bv METHODS AND PROCEDURES FOR MANUFACTURING HIGH EFFICIENCY ANTIBODIES
TR201809128T4 (tr) 2009-07-15 2018-07-23 Aimm Therapeutics Bv Gram-pozitif bakterilere spesifik bağlanan bileşikler.
ES2626671T3 (es) * 2010-12-02 2017-07-25 Aimm Therapeutics B.V. Medios y métodos para producir anticuerpos de alta afinidad
CN102559733A (zh) * 2012-03-13 2012-07-11 黑龙江省科学院微生物研究所 导入clfA基因的乳酸乳球菌基因工程菌株的构建方法
UY34887A (es) 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
CN104968797B (zh) 2012-11-06 2018-11-30 米迪缪尼有限公司 金黄色葡萄球菌表面决定簇的抗体
WO2014142117A1 (ja) * 2013-03-12 2014-09-18 全薬工業株式会社 抗ブドウ球菌抗体、その製造方法並びにその使用
AR095199A1 (es) * 2013-03-15 2015-09-30 Genzyme Corp Anticuerpos anti-cd52
US9803002B2 (en) 2013-05-31 2017-10-31 Genentench, Inc. Anti-wall teichoic antibodies and conjugates
BR112015029754A2 (pt) 2013-05-31 2017-09-26 Genentech Inc anticorpos anti-teicoico da parede e conjugados
MA38686A1 (fr) * 2013-05-31 2017-10-31 Genentech Inc Anticorps anti-acide téichoïque de la paroi cellulaire et conjugués associés
AU2014323523B2 (en) 2013-09-20 2020-02-20 Bristol-Myers Squibb Company Combination of anti-LAG-3 antibodies and anti-PD-1 antibodies to treat tumors
KR20240042192A (ko) 2013-12-17 2024-04-01 크링 바이오테라퓨틱스 비.브이. 골수 증식성 또는 림프 증식성 질환에 대응하는 수단 및 방법
WO2015115892A1 (en) 2014-01-31 2015-08-06 Aimm Therapeutics B.V. Means and methods for producing stable antibodies
JP6751393B2 (ja) * 2014-12-03 2020-09-02 ジェネンテック， インコーポレイテッド 抗ｓｔａｐｈｙｌｏｃｏｃｃｕｓ ａｕｒｅｕｓ抗体リファマイシン抱合体及びその使用
KR20170086536A (ko) * 2014-12-03 2017-07-26 제넨테크, 인크. 항-스타필로코커스 아우레우스 항체 리파마이신 접합체 및 이의 용도
WO2016200926A1 (en) * 2015-06-09 2016-12-15 Techulon Inc. Peptide nucleic acid molecules for treatment of gram positive bacterial infection
EP3368074A2 (en) 2015-10-30 2018-09-05 Hoffmann-La Roche AG Anti-factor d antibodies and conjugates
US10738338B2 (en) 2016-10-18 2020-08-11 The Research Foundation for the State University Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate
KR102721137B1 (ko) 2017-05-30 2024-10-25 브리스톨-마이어스 스큅 컴퍼니 항-lag-3 항체 또는 항-lag-3 항체 및 항-pd-1 또는 항-pd-l1 항체를 포함하는 조성물
CA3060984A1 (en) 2017-05-30 2018-12-06 Bristol-Myers Squibb Company Treatment of lag-3 positive tumors
US11280788B2 (en) 2019-01-31 2022-03-22 Fresenius Medical Care Holdings, Inc. Rapid diagnosis of peritonitis in peritoneal dialysis patients
KR102301987B1 (ko) * 2019-11-14 2021-09-13 연세대학교 산학협력단 항체 선별 방법, 박테리아 오염 진단 방법 및 박테리아 오염 진단 키트
US20240101666A1 (en) 2020-10-23 2024-03-28 Bristol-Myers Squibb Company Lag-3 antagonist therapy for lung cancer
WO2023129822A2 (en) * 2021-12-28 2023-07-06 The Board Of Trustees Of The Leland Stanford Junior University Chemically modified bacterial peptidoglycan compositions and uses thereof

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995034655A2 (en) 1994-06-07 1995-12-21 The Rockefeller University Surface protein of staphylococcus aureus
US6008341A (en) 1994-08-22 1999-12-28 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin S. aureus fibrinogen binding protein gene
US6994855B1 (en) 1994-08-22 2006-02-07 The Provost Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin S. aureus fibrinogen binding protein gene
CA2208780C (en) * 1995-01-30 2010-03-30 Peter Truog Antitumor and anticholesterol preparations comprising lipoteichoic acid lta-t of streptococcus sp dsm 8747
SE9602496D0 (sv) 1996-06-20 1996-06-20 Bengt Guss Method and means for producing a fibrinogen binding protein and its use in biotechnology
US6610293B1 (en) 1997-06-16 2003-08-26 The Henry M. Jackson Foundation For The Advancement Of Military Medicine Opsonic and protective monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria
US6680195B1 (en) 1997-11-26 2004-01-20 Inhibitex, Inc. Extracellular matrix-binding proteins from staphylococcus aureus
US6322788B1 (en) * 1998-08-20 2001-11-27 Stanley Arthur Kim Anti-bacterial antibodies and methods of use
WO2000012132A1 (en) 1998-08-31 2000-03-09 Inhibitex, Inc. Staphylococcal immunotherapeutics via donor selection and donor stimulation
US6692739B1 (en) * 1998-08-31 2004-02-17 Inhibitex, Inc. Staphylococcal immunotherapeutics via donor selection and donor stimulation
AU771426B2 (en) 1998-08-31 2004-03-18 Inhibitex, Inc. Multicomponent vaccines
US6703025B1 (en) 1998-08-31 2004-03-09 Inhibitex, Inc. Multicomponent vaccines
BR9913311A (pt) 1998-08-31 2001-10-16 Trinity College Dublin Molécula de ácido nucleico isolado, ácido nucleico isolado, vetor, proteìna, anticorpo e anti-soros formados contra uma proteìna, kit de diagnóstico, processos para reduzir a infecção de estafilococos coagulase-negativos de um dispositivo médico de retenção, para tratar uma infecção de estafilococus coagulase-negativa, para prevenir uma infecção de estafilococos coagulase-negativa em um paciente, para induzir uma resposta imunológica e para identificar compostos que inibem estafilococos coagulase-negativos
US20030165527A1 (en) 1998-12-22 2003-09-04 Bengt Guss Novel fibronectin-binding protein
US20040038327A1 (en) 1999-08-31 2004-02-26 Foster Timothy J. Antibodies to polypeptides from coagulase-negative staphylococci
CN1489474A (zh) * 2001-01-26 2004-04-14 Ӣϣ��̩��˹��˾ 针对clfa蛋白质的单克隆抗体和在治疗或预防感染中的利用方法
GB0127983D0 (en) * 2001-11-22 2002-01-16 Neutec Pharma Plc Treatment of micro-organism infection
AU2003210060B2 (en) 2002-03-22 2010-02-25 Aprogen, Inc. Humanized antibody and process for preparing same
EP1540559B1 (en) 2002-09-13 2013-02-27 The Texas A & M University System Bioinformatic method for identifying surface-anchored proteins from gram-positive bacteria and proteins obtained thereby
US20040151737A1 (en) 2003-02-05 2004-08-05 University Of Tennessee Streptococcal serum opacity factors and fibronectin-binding proteins and peptides thereof for the treatment and detection of streptococcal infection
WO2004080490A2 (en) 2003-03-07 2004-09-23 Wyeth Holdings Corporation Polysaccharide - staphylococcal surface adhesin carrier protein conjugates for immunization against nosocomial infections
CA2526753A1 (en) 2003-05-29 2004-12-23 Inhibitex, Inc. Sdr proteins from staphylococcus capitis and their use in preventing and treating infections
ES2579805T3 (es) * 2004-09-23 2016-08-16 Genentech, Inc. Anticuerpos y conjugados modificados por ingeniería genética con cisteína
EP1850867A1 (en) * 2005-01-10 2007-11-07 Nabi Biopharmaceuticals Method of treating staphylococcus aureus infection
WO2006138627A2 (en) 2005-06-16 2006-12-28 Inhibitex, Inc. Monoclonal antibodies recognizing a coagulase-negative staphylococcal protein
WO2007100580A2 (en) 2006-02-22 2007-09-07 The Texas A & M University System Antibodies recognizing a highly expressed putative antigen of ca-mrsa and methods of use
CN103351435B (zh) * 2006-06-06 2015-08-19 克鲁塞尔荷兰公司 具有杀灭葡萄球菌活性的人结合分子及其应用
US20100209434A1 (en) * 2007-03-30 2010-08-19 Medimmune, Llc Antibody formulation
TW200902554A (en) 2007-05-08 2009-01-16 Genentech Inc Cysteine engineered anti-MUC16 antibodies and antibody drug conjugates
CN101302504B (zh) * 2007-05-11 2011-12-21 上海高科联合生物技术研发有限公司 一种抗体亲和层析纯化溶葡萄球菌酶的方法
ATE543835T1 (de) 2007-07-16 2012-02-15 Genentech Inc Anti-cd79b-antikörper und immunkonjugate und anwendungsverfahren
ES2528922T3 (es) 2007-07-16 2015-02-13 Genentech, Inc. Anticuerpos anti-CD79b humanizados e inmunoconjugados y métodos de uso
US20090162379A1 (en) 2007-10-01 2009-06-25 Magnus Hook Inhibitors of S. aureus SdrD protein attachment to cells and uses therefor
AU2008312457B2 (en) 2007-10-19 2014-04-17 Genentech, Inc. Cysteine engineered anti-TENB2 antibodies and antibody drug conjugates
EA019516B1 (ru) 2008-01-31 2014-04-30 Де Провост, Феллоус Энд Сколарс Оф Де Колледж Оф Де Хоули Энд Андивайдид Тринити Оф Куин Элизабет, Неар Дублин Лечение микробных инфекций
PT2247620T (pt) 2008-01-31 2016-08-23 Genentech Inc Anticorpos e imunoconjugados anti-cd79b e métodos de utilização
WO2010005513A2 (en) 2008-06-30 2010-01-14 The Texas A&M University System Crystal structure of staphylococcus aureus clumping factor a in complex with fibrinogen derived peptide and uses thereof
CN102481352A (zh) 2009-06-22 2012-05-30 惠氏有限责任公司 金黄色葡萄球菌抗原的免疫原性组合物
TR201809128T4 (tr) 2009-07-15 2018-07-23 Aimm Therapeutics Bv Gram-pozitif bakterilere spesifik bağlanan bileşikler.
WO2011007004A1 (en) 2009-07-16 2011-01-20 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin Treatment of infections

Also Published As

Publication number Publication date
US9927428B2 (en) 2018-03-27
US20170067880A1 (en) 2017-03-09
US20130261293A1 (en) 2013-10-03
WO2011008092A4 (en) 2011-07-07
BR112012000953A2 (pt) 2016-11-22
CN102666583A (zh) 2012-09-12
ZA201400644B (en) 2015-10-28
US9458228B2 (en) 2016-10-04
US20180292391A1 (en) 2018-10-11
US20160168232A9 (en) 2016-06-16
IL217497A (en) 2015-11-30
SI2454284T1 (en) 2018-07-31
HUE038277T2 (hu) 2018-10-29
US20140235828A1 (en) 2014-08-21
MX350234B (es) 2017-08-30
TW201107470A (en) 2011-03-01
US20130253175A1 (en) 2013-09-26
IL242207A0 (en) 2015-11-30
CN105440133A (zh) 2016-03-30
AU2016250398A1 (en) 2016-11-17
CA2768204A1 (en) 2011-01-20
CN102666583B (zh) 2015-11-25
NZ616921A (en) 2015-06-26
NZ598063A (en) 2014-07-25
US8617556B2 (en) 2013-12-31
WO2011008092A2 (en) 2011-01-20
BR112012000953A8 (pt) 2017-12-26
ES2673323T3 (es) 2018-06-21
HK1222418A1 (zh) 2017-06-30
ZA201200363B (en) 2014-06-25
EP2454284B1 (en) 2018-04-11
IL217497A0 (en) 2012-02-29
JP6192294B2 (ja) 2017-09-06
US20150376266A1 (en) 2015-12-31
US20120157665A1 (en) 2012-06-21
KR20120065326A (ko) 2012-06-20
US9688745B2 (en) 2017-06-27
PL2454284T3 (pl) 2018-09-28
TWI502068B (zh) 2015-10-01
EA031447B1 (ru) 2019-01-31
JP2018134089A (ja) 2018-08-30
AU2010271582B2 (en) 2016-07-28
AU2010271582A1 (en) 2012-03-01
US9399673B2 (en) 2016-07-26
IL238074A (en) 2016-06-30
SG177653A1 (en) 2012-02-28
EA201390967A1 (ru) 2014-01-30
US20160222096A1 (en) 2016-08-04
AR077756A1 (es) 2011-09-21
TW201610153A (zh) 2016-03-16
US9266943B2 (en) 2016-02-23
AU2016250398B2 (en) 2018-09-27
JP2012533293A (ja) 2012-12-27
WO2011008092A3 (en) 2011-05-26
KR101832201B1 (ko) 2018-02-28
DK2454284T3 (en) 2018-07-02
EP2454284A2 (en) 2012-05-23
SG10201704269RA (en) 2017-06-29
JP2016135771A (ja) 2016-07-28
AU2010271582A2 (en) 2013-05-16
US9090677B2 (en) 2015-07-28
US20110020323A1 (en) 2011-01-27

Similar Documents

Publication Publication Date Title
SI2454284T1 (en) Compounds that specifically bind to Gram-positive bacteria
TR201817932T4 (tr) Staphylococcus aureus alfa toksi̇ni̇ni̇ spesi̇fi̇k olarak bağlayan anti̇korlar ve kullanim yöntemleri̇
RU2014143785A (ru) Фармацевтическая композиция для лечения и/или предотвращения рака печени
JP6182152B2 (ja) 抗シュードモナス属（Ｐｓｅｕｄｏｍｏｎａｓ）ＰｓｌおよびＰｃｒＶ結合分子を用いた併用治療
JP2020037555A5 (tr)
RU2014143784A (ru) Фармацевтическая композиция для лечения и/или предотвращения рака желчного пузыря
RU2015121624A (ru) Антитела к поверхностным детерминантам s. aureus
RU2014108047A (ru) Фармацевтическая композиция для лечения и/или профилактики рака поджелудочной железы
IL253462B (en) Cancer treatment with monoclonal antibodies against latency-associated peptide
JP2014508748A5 (tr)
RU2016100892A (ru) Антитела против tweakr и их применение
RU2018102606A (ru) Молекулы, связывающиеся с psl pseudomonas, и пути их применения
RU2015121617A (ru) Способы лечения заболеваний, ассоциированных с s. aureus
EA032189B9 (ru) Изолированные человеческие моноклональные антитела против ингибитора пути тканевого фактора (tfpi) и фармацевтическая композиция, содержащая их
HRP20190917T1 (hr) NEUTRALIZIRAJUĆA PROTUTIJELA NA GLAVNE EKSOTOKSINE TcdA i TcdB CLOSTRIDIUM DIFFICILE
WO2020023644A3 (en) Antibody directed against s. aureus clumping factor a (clfa)
JP2016047828A5 (tr)
RU2011146424A (ru) Антитела или их фрагменты, направленные против эпитопа стафилококка золотистого (staphylococcus aureus)
AU2011295702A1 (en) Staphylococcus aureus specific human recombinant polyclonal antibodies and uses thereof
IL277899B2 (en) Methods and preparations for treating yellow fever
WO2014061783A1 (ja) クロストリジウム・ディフィシルの毒素に特異的なヒト抗体もしくはその抗原結合性断片
NZ606828A (en) Human binding molecules having killing activity against enterococci and staphylococcus aureus and uses thereof
Kabir et al. Peptide derived from anti-idiotypic single-chain antibody is a potent antifungal agent compared to its parent fungicide HM-1 killer toxin peptide
AU2010282162B2 (en) Monoclonal antibodies against the PBP2-a protein and homologous sequences for the treatment of infections by and immunodiagnostics of bacteria of the firmicutes phylum
CA2770771C (en) Monoclonal antibodies for pbp2-a protein and homologous sequences for treatment of infections and immunodiagnosis on bacteria from phylum firmicutes